Search

Displaying results 5131 - 5140 of 10000 in total
  1. Drug

    Clioquinol

    go.drugbank.com/drugs/DB04815
    ApprovedVet approvedWithdrawn

    Clioquinol was withdrawn in 1983 due to neurotoxicity.

  2. Drug

    Talampanel

    go.drugbank.com/drugs/DB04982
    Investigational

    Talampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.

  3. Drug

    CRx-401

    go.drugbank.com/drugs/DB05775
    Experimental

    has proven to be well tolerated in clinical trials. … In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and lipid profiles, and this dose

  4. Drug

    Carthamus tinctorius flower bud

    go.drugbank.com/drugs/DB14278
    Approved

    Carthamus tinctorius flower bud is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Zanthoxylum clava-herculis whole

    go.drugbank.com/drugs/DB14353
    Approved

    Zanthoxylum clava-herculis whole is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  6. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.

  7. Drug

    NS-3728

    go.drugbank.com/drugs/DB05835
    Experimental

    NS3728 is an orally active chloride channel blocker for the treatment of cancer.

    Synonyms: N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea
  8. Drug

    OPC-51803

    go.drugbank.com/drugs/DB05838
    Experimental

    It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of urinary incontinence. … It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states.

  9. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

  10. Drug

    Ropidoxuridine

    go.drugbank.com/drugs/DB06485
    Investigational

    Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.